Results 91 to 100 of about 15,334 (193)

Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells. [PDF]

Front Immunol
Nianias A, Katsarou A, Prins HJ, Shahrabi A, van Velzen C, Henneman L, Ruiter R, Mutis T, Groen R, Themeli M.   +9 more
europepmc   +1 more source

Imaging CRISPR-edited CAR-T cell therapies with optical and positron emission tomography reporters. [PDF]

Theranostics
Sanchez-Pupo RE, Kelly JJ, Shalaby N, Xia Y, Martinez-Santiesteban FM, Lau J, Verriet IE, Fox MS, Hicks JW, Thiessen JD, Ronald JA.   +10 more
europepmc   +1 more source

Beyond autologous <i>ex vivo</i> CAR-expressing cell therapies: Toward allogeneic and nucleated cell-free delivery systems of CAR. [PDF]

Mol Ther Oncol
Rallis KS, Dionisio LM, Tarannum M, Romee R, Cancelas JA.   +4 more
europepmc   +1 more source

Séminaire Tracs : Francophonie

Transatlantic Cultures, 2022
openaire   +1 more source

Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease. [PDF]

Biology (Basel)
Osborne M, Maher J.
europepmc   +1 more source

Therapeutic applications of CRISPR-Cas9 gene editing. [PDF]

Front Genome Ed
Bharti A, Mudge J.
europepmc   +1 more source

Double-strand break-free epigenetic programming: a safer path for T-cell therapies. [PDF]

Signal Transduct Target Ther
Deng L, Yang Y, El-Osta A, El-Osta A.
europepmc   +1 more source

Improving CAR T cell therapy against malignancies through gene knock-down/out strategies: a systematic review. [PDF]

Cancer Cell Int
Karimi A, Kazemi-Harikandei SZ, Alilou S, Salabat D, Pourfaraji SM, Shirmard FO, Seighali N, Maleki S, Akbari B, Noorbakhsh F, Hadjati J, Mirzaei HR.   +11 more
europepmc   +1 more source

Trac et pâtes

Caramel, 2020
openaire   +2 more sources

Séminaire TRACS 2022-2023: programme

Transatlantic Cultures, 2022
openaire   +2 more sources